(GOVX) GeoVax Labs, Inc. Business Model Canvas Research

Emory University is a key academic partner for GeoVax Labs, Inc., supporting scientific validation, preclinical work, and clinical design through access to specialized labs and expert researchers. This kind of tie helps speed translational research in a field where one failed preclinical step can delay a program by months or years.

• Validates science with academic rigor
• Supports preclinical and clinical know-how
• Expands access to research infrastructure

GeoVax’s links with the University of Pittsburgh and the Burnet Institute give it 2 key academic partners for infectious-disease and immunology work. These ties support shared vaccine and therapeutic research, helping the Company widen its science base without building every capability in-house.

• 2 academic partners
• Broadens immunology reach
• Supports shared R&D

GeoVax Labs, Inc. relies on partnership-driven translational research with 3 core public-sector anchors — NIH, CDC, and DoD — plus university collaborators. These ties support preclinical and translational studies, while sharing scientific risk and development cost across multiple programs.

• 3 federal anchors: NIH, CDC, DoD
• University partners extend study capacity
• Shares risk and lowers R&D burden

GeoVax’s key activity here is CMC and manufacturing readiness: locking down process controls, GMP supply, and FDA-facing regulatory plans so its vaccine and immunotherapy candidates can move from Phase 2 into Phase 3 and, later, commercialization. One line: no clean manufacturing path, no late-stage trial scale-up.

• CMC plans support FDA review
• GMP scale-up enables Phase 3
• Process readiness lowers launch risk

GeoVax’s value in biotech rests on proprietary know-how, patentable designs, and the know-how embedded in its vaccine platforms. These intangible assets can help defend the business, support licensing talks, and create future commercialization options if candidates move into late-stage development.

• Patents protect candidate designs
• Know-how is hard to copy
• IP can support licensing deals
• Platform assets drive future value

GeoVax Labs, Inc. is headquartered in Smyrna, Georgia, in the Atlanta metro area, and that site supports management, scientific coordination, and corporate operations. For a clinical-stage biotech with 1 core U.S. HQ, this central base anchors the company’s development footprint and keeps decision-making close to its research network.

• Smyrna, Georgia HQ
• Management and science coordination
• Corporate operations hub

GeoVax’s biodefense proposition centers on four high-priority pathogens: Ebola, Sudan, Marburg, and Lassa. That focus fits U.S. government and public-health demand because these are outbreak-capable threats, and the company’s MVA vaccine platform is aimed at rapid-response preparedness, not just routine commercial use.

• Four priority outbreak threats
• Biodefense and public-health demand
• Built for rapid response

GeoVax’s value proposition is a dual-use pipeline that spans prophylactic vaccines and therapeutic immunotherapies, so one core platform can serve prevention and treatment. That broadens its addressable market and creates multiple shots on goal across infectious disease and oncology programs.

• One platform, two revenue paths
• Prevention plus treatment markets
• More program options from one core tech

Patient and volunteer trial interaction at GeoVax Labs, Inc. is driven by clinical trial operations, with every participant managed under informed consent and safety rules. Under U.S. GCP standards, serious adverse events must be reported within 15 calendar days, and IRB review is required at least once a year, so the relationship is tightly regulated and site-led.

• Safety and consent first
• Operates through trial sites
• Highly regulated GCP process

GeoVax Labs uses partner-led milestone management to keep collaboration work tied to clear deliverables, review points, and shared technical updates. In biotech, this model fits funded programs because payments and next steps usually depend on milestone hits, which strengthens accountability and helps control R&D burn.

• Clear deliverables
• Scheduled progress reviews
• Shared technical data
• Milestone-linked accountability

GeoVax Labs, Inc. uses scientific conferences and peer-reviewed publications to share preclinical and clinical data, which helps reach researchers, funders, and partners. In 2025, the company had $0 product revenue and reported a net loss of $28.9 million, so these low-cost channels are key for visibility and scientific credibility.

• Shares data with experts fast
• Builds partner and funder awareness
• Supports scientific reputation

GeoVax Labs, Inc. likely relies on direct outreach for licensing and partnership talks because it is still clinical-stage and had 0 commercial product sales in its latest reporting cycle. This channel matters more here than mass sales, since it supports deal-making with institutions and industry without a mature sales force.

• Targets licensors and co-development partners
• Fits a 0-sales commercial model
• Supports institutional deal flow

GeoVax’s oncology buyers are researchers, cancer centers, and biotech partners focused on solid-tumor immunotherapy, a market tied to the 10+ million global cancer deaths reported by WHO in 2022. This segment is separate from infectious-disease users because it needs different trial designs, endpoints, and translational support.

• Solid-tumor focus

• Research and institutional buyers

• Partnership-driven demand

Clinical trial participants and patient populations are GeoVax Labs, Inc.'s core execution segment: patients and healthy volunteers supply the clinical evidence needed for development, but they are not revenue customers. Trial sizes usually range from dozens in early studies to thousands in late-stage trials, so enrollment quality and retention directly shape data strength and timeline.

• Patients and volunteers enable trial evidence
• Not revenue buyers, but essential users
• Enrollment scale can reach thousands

Manufacturing and CMC work are a major cost driver for GeoVax Labs, Inc., because process development, formulation, scale-up, and quality systems must be in place before later-stage trials and any commercial launch. For a clinical-stage biotech, these spend items are not optional: they support batch consistency, regulatory readiness, and supply for pivotal studies.

• Process development raises upfront spend.
• Scale-up adds CMC and QA costs.
• Quality systems support trial and launch readiness.

GeoVax Labs, Inc. carries steady regulatory, legal, and overhead costs because it must keep IP protected, file reports, and maintain strong governance and records. For a clinical-stage biotech, these fixed costs stay high even before product sales, and they often sit alongside G&A spend that can run well above 20% of total operating expense in development-heavy years.

• IP protection and patent upkeep
• SEC reporting and audit support
• Board, admin, and legal overhead
• Heavy documentation for trials

GeoVax Labs, Inc. can monetize its platform and vaccine candidates through licenses and partner option deals, a standard revenue path for platform biotech. In practice, cash often starts with upfront option fees, then can expand through milestones and royalties if a partner advances the program.

• Licenses can turn IP into cash.
• Options can bring upfront partner fees.
• Milestones and royalties add upside.

GeoVax Labs, Inc. expects future product sales to become meaningful only if candidates win approval, turning its pipeline into commercial revenue. Royalties could also come from out-licensed products, but these streams are still prospective, not established; GeoVax Labs, Inc. has not yet built a large recurring product-sales base.

• Approval needed for commercial sales
• Royalties may come from licensing
• Revenue is still prospective today